Roger Seheult MD
Critical Care Medicine, Pleural Disease, Sleep Medicine
Pulmonary/Critical Care/Sleep Physician at Renew Medical Group
Join to View Full Profile
6109 W Ramsey StreetBanning, CA 92220
Phone+1 951-845-0313
Fax+1 951-845-8194
Dr. Seheult is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Roger Seheult is a pulmonologist based in Banning, CA, with subspecialties in critical care medicine, pulmonary disease, and sleep medicine. He completed his medical education at Loma Linda University School of Medicine in 2000, followed by a residency in internal medicine and a fellowship in pulmonary disease and critical care medicine at Loma Linda University Health. He is the co-founder of MedCram.com and has academic appointments at Loma Linda University and UCR.
Education & Training
Loma Linda University Health Education ConsortiumFellowship, Pulmonary Disease and Critical Care Medicine, 2004 - 2007- Loma Linda University Health Education ConsortiumResidency, Internal Medicine, 2000 - 2003
Loma Linda University School of MedicineClass of 2000
Certifications & Licensure
CA State Medical License 2001 - 2027
American Board of Internal Medicine Internal Medicine- American Board of Internal Medicine Critical Care Medicine
- American Board of Internal Medicine Pulmonary Disease
- American Board of Internal Medicine Sleep Medicine
Publications & Presentations
PubMed
- An evaluation of vilobelimab (anti-C5a) as a cost-effective option to treat severely ill mechanically ventilated patients with COVID-19.Daniel C Malone, Joseph Biskupiak, Diana Brixner, Gary Oderda, Roger Seheult
American Journal of Health-System Pharmacy. 2024-10-30 - 7 citationsClinical outcomes of prolonged anticoagulation with rivaroxaban after unprovoked venous thromboembolism.Jeffrey S. Berger, Roger Seheult, François Laliberté, Concetta Crivera, Dominique Lejeune
Research and Practice in Thrombosis and Haemostasis. 2018-01-01 - 6 citationsRisk for Venous Thromboembolism Recurrence Among Rivaroxaban-treated Patients Who Continued Versus Discontinued Therapy: Analyses Among Patients with VTE☆Alok A. Khorana, Jeffrey S. Berger, Philip S. Wells, Roger Seheult, Veronica Ashton
Clinical Therapeutics. 2017-07-01
Press Mentions
Ensifentrine (Ohtuvayre) for COPD: 2024 FDA Approval, ENHANCE Trials, and What You Need to KnowApril 29th, 2025- Flu Vaccine Linked to Higher Infections, Says Early ResearchApril 9th, 2025
- Show 1424: Breathing Better Despite Pollution, Infections, Asthma or COPDMarch 27th, 2025
- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
